drugset / Trial / NCT03823079

Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia

NCT03823079

Phase 2 Unknown 50 enrolled Fudan University
RandomizedParallel-groupOpen-labelTreatment

Summary

This randomized controlled clinical phase II study was designed to compare the effect of rhTPO with rhIL-11 in improving thrombocytopenia in patients with recurrent colorectal cancer who underwent radiotherapy and with thrombocytopenia.

Timeline

Start
2019-02-01
Primary completion
2019-09-01
Completion
2020-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject recombinant human thrombopoietin Protein / enzyme biologic 300 iu/kg Subcutaneous
Comparator rhIL-11 Protein / enzyme biologic 50 ug/kg Subcutaneous
Background Irinotecan Small molecule 65 mg/m2
Background Irinotecan Small molecule 80 mg/m2
Background Raltitrexed Small molecule 3 mg/m2